Supatcha Resources Inc. (OTC Bulletin Board: SAEI) reached up 68.25% in morning trading to $.53 with 2M shares traded. Supatcha Resources Inc. is a gold exploration company focused on acquiring and developing mineral properties in Ukraine. Supatcha is in the final stages of acquiring two additional gold mining projects, with world-class potential, in southwestern Ukraine. Supatcha Resources Inc. (OTC Bulletin Board:SAEI.ob - News) ("Supatcha" or the "Company") is pleased to announce the results of the first NI 43-101 compliant resource estimate for the Barlevskoye and Vynohradiv Gold Property. NEOSC Geomin Ltd. (NGL) has completed a mineral resource estimate for the Barlevskoye and Vynohradiv Deposit effective December 6, 2010.
CyberDefender Corporation (Nasdaq: CYDE) reached up 36.70% in morning trading to $2.57 with 400K shares traded. CyberDefender is a provider of Internet security software, utilities and remote technical support services that work together to ensure maximum safety for consumers in a digital world. The company develops and markets antispyware/antivirus software and a remote, live technical support service. In addition, CyberDefender offers identity protection and computer optimization services. With millions of active users on its cloud based collaborative Internet security network, CyberDefender leverages the power of community to protect its customers from the rapidly growing number of new online threats every year. CyberDefender products are fully compatible with Microsoft Windows(R) XP, Vista(R), and 7 Operating systems. CyberDefender Corporation (Nasdaq:CYDE - News) ("CyberDefender") today announced that it expects to file its amended financial reports and regain NASDAQ compliance before December 31, 2010.
Novelos Therapeutics, Inc. (OTC Bulletin Board: NVLT) reached up 40.91% in morning trading to $.031 with 6M shares traded. Novelos Therapeutics, Inc. is a biopharmaceutical company developing oxidized glutathione-based compounds for the treatment of cancer. Their lead compound, NOV-002, has been administered to approximately 1,000 cancer patients in clinical trials and is in Phase 2 development for solid tumors in combination with chemotherapy. Novelos is seeking to expand their pipeline through licensing or acquiring clinical stage compounds or technologies for oncology indications. Novelos Therapeutics, Inc. (OTCBB:NVLT.ob - News) announced that today a poster highlighting positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer is being presented by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine at the AACR Breast Cancer Symposium in San Antonio, TX. Alberto Montero, MD, Assistant Professor of Medicine at the Miller School and medical oncologist at Sylvester, is the Principal Investigator.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
